Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The present study was undertaken to investigate the effects of dopaminergic agents and hypothalamic-releasing hormones on the GH release in acromegalics and normal volunteers. In the methylphenidate (Ritalin) test, nine normal volunteers and four acromegalics were examined. In other tests, five acromegalics were examined. The dopaminergic agents were administered to the subjects orally early in the morning after overnight fasting, but the hypothalamic-releasing hormones were given intravenously at the same time. The results were as follows: (1) The oral administration of 20 mg of Ritalin failed to have any effect on the GH release in normal subjects, and caused a decrease of serum GH level in only one of four acromegalics, the same case which showed an increased GH response to 1-DOPA. In the other three patients, Ritalin did not effect the GH release. Long-term administration of this drug to the acromegalics who showed depression of GH levels resulted in only slightly depressed GH levels. (2) Each oral administration of 2.5 mg of CB-154 or 500 mg of 1-DOPA caused a significant decrease of serum GH level in acromegalics, but CB-154 showed a longer and more stable suppression of serum GH level in all acromegalics. Furthermore, long-term administration of this drug resulted in a continuing inhibited serum GH level without the existence of any serious side effects. It thus seems likely that CB-154 might be a safe and effective drug for the medical treatment of acromegalics. However, while 1-DOPA also caused a significant decrease of serum GH level in four out of five acromegalics, its effect was of much shorter duration. (3) The intravenous administration of 500 microgram of TRH showed a significant increase of serum GH level in four out of five acromegalics, but LH-RH did not have any effect on GH release in any of the acromegalic cases. It seems likely from these results that dopaminergic agents, especially CB-154, may be beneficial for the medical treatment of acromegaly.
 ...
PMID:[The effect of Ritalin, CB-154 and various drugs of serum GH in acromegalics (author's transl)]. 9 32

Psychostimulants, including ritalin (methylphenidate), were used as antidepressives in the '50s but were then replaced by tricyclics and MAO inhibitors. Treatment of depression with psychostimulants is still controversial. Several anecdotal reports in the past decade approved the use of tricyclic antidepressants (TCA) together with methylphenidate in apathetic and withdrawal states in medically ill and in elderly patients. Ritalin elevates mood by releasing catecholamines and blocking their re-uptake, and also increases serum TCA levels. 5 men and 5 women between the ages of 65 and 79 were diagnosed as suffering from major depressive disorders, either single or recurrent, based on the Revised Diagnostic and Statistical Manual for Mental Disorders (DSM-III-R). They had been treated with TCA for up to several months with no response. Following addition of methylphenidate, 5-15 mg/d for 2 weeks, 4 men and 3 women improved rapidly, 2 of them within 24 hours.
 ...
PMID:[Combined tricyclic antidepressants and ritalin in elderly depressives]. 145 98

Methylphenidate hydrochloride (Ritalin) has been used to treat both depression and apathy. Although it can be useful for apathy, there is little reason to prefer it over a tricyclic antidepressant in the treatment of depression. Side effects and drug interactions are generally not limiting, and methylphenidate is tentatively recommended for the patient whose apathy is jeopardizing his care.
 ...
PMID:Methylphenidate in depression and states of apathy. 701 85

Attention-deficit hyperactivity disorder (ADHD) has been considered a mental and behavioral disorder of childhood and adolescence. It is being increasingly recognized in adults, who may have psychiatric co-morbidity with secondary depression, or a tendency to drug and alcohol abuse. We describe a 32-year-old woman known for years as suffering from borderline personality disorder and drug dependence (including hashish, marijuana, LSD and "ecstasy") and alcohol abuse that did not respond to treatment. Only when correctly diagnosed as ADHD and appropriately treated with the psychotropic stimulant, methylphenidate (Ritalin), was there significant improvement. She succeeded academically, which had not been possible previously, the craving for drugs diminished and a drug-free state was reached. Although administration of psychostimulants to drug abusers is controversial, as they are addictive, in cases of ADHD they have promoted drug abstinence.
 ...
PMID:[Attention deficit hyperactivity disorder, facilitating alcohol and drug abuse in an adult]. 922 72

Methylphenidate (Ritalin, manufacturer: Ciba/Geigy) has been shown effective for the treatment of depression in various medically ill populations, but to our knowledge its use in organ transplant patients has not been described. The authors retrospectively reviewed clinical records of the first eight inpatients who received methylphenidate for treatment of depressive and/or cognitive symptoms in the post liver transplant period at Mount Sinai Medical Center. Target symptoms included psychomotor and cognitive slowing as well as lack of motivation for recovery, poor rehabilitation effort, social withdrawal, and apathy. A positive response was noted in seven patients, and in one patient the response was equivocal. Side effects noted were increased blood pressure (N = 2) and subjective restlessness/agitation (N = 3). Methylphenidate appears to be an effective, rapidly acting agent in this setting at dosages of 10-20 mg/day, with minimal side effects. Methylphenidate may have a significant role in the care of an ever-increasing population of organ transplant recipients with multiple medical problems and associated disabilities.
 ...
PMID:Methylphenidate in post liver transplant patients. 958 37

Methylphenidate (Ritalin) is a commonly used central nervous stimulant. It has been used in various neurological conditions, including attention deficit disorder, depression, and narcolepsy. Methylphenidate has been advocated in patients with traumatic brain injury and stroke for a variety of cognitive, attention, and behavioral problems. It also has been shown to speed recovery from poststroke depression so that patients can participate more fully in rehabilitation programs. Research suggests that it also may have a role in augmenting activity of injured neuronal tissue in the comatose patient, thus facilitating a return to consciousness. The neuroscience nurse plays an important role in monitoring response to Ritalin, including identifying its side effects. A review of the limited studies on the use of Ritalin, its mechanisms of action, dosing, and weaning provide a current understanding of this adjunctive agent's role in treatment for the neurological population.
 ...
PMID:Ritalin revisited: does it really help in neurological injury? 1250 13

This study examines how Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants have played a contributing role in expanding categories of women's "mental illness" in relation to categories of "normal" behavior. We hypothesized that between 1985 and 2000, as Premenopausal Dysphoric Disorder (PMDD), postpartum depression, and perimenopausal depression were increasingly treated with SSRIs, popular categories of depressive illness expanded to encompass what were previously considered normative women's life events such as motherhood, menstruation, or child birth. We quantified and qualified this expansion through an in-depth analysis of popular representations of depressive illness during the time period when SSRIs were introduced. Using established coding methods, we analyzed popular articles about depression from a mix of American magazines and newspapers spanning the years 1985-2000. Through this approach, we uncovered a widening set of gender-specific criteria outside of the Diagnostic and Statistical Manual criteria for dysthymic or depressive disorders that have, over time, been conceived as indicative of treatment with SSRIs. Our results suggest that SSRI discourse may have helped shift popular categories of "normal/acceptable" and "pathological/treatable" womanhood, in much the same way that the popularity of Ritalin has shifted these categories for childhood.
 ...
PMID:Assessing the impact of SSRI antidepressants on popular notions of women's depressive illness. 1465 53

Asthma is a global health problem with up to 15% of children suffering from the disease. It has been shown by various researchers that symptomatic asthmatic patients have increased levels of free serotonin in plasma when compared with asymptomatic patients. Thus, some researchers suggest that reducing the concentration of free serotonin in plasma might be useful in treating patients with asthma. Low levels of serotonin, has however, been linked to various psychological conditions like depression, oppositional defiant disorder, ADHD and even conduct disorder. Research has indicated that products like methylphenidate (also known by the brand names as e.g., Ritalin, Concerta, Metadate and others) and other stimulants used for these conditions, particularly ADHD, exert their paradoxical calming effects by boosting serotonin levels in the brain. Therefore, the hypothesis suggest that some children using asthma medication that lowers serotonin levels, might present with symptoms of depression ADHD, oppositional defiant disorder and even conduct disorder. They may be using asthma medication that lowers serotonin and additionally use methylphenidate that boosts serotonin levels for e.g., ADHD. The hypothesis therefore suggests that asthmatic children presenting with psychological complaints, be treated holistically and serotonin levels measured before coming to conclusions regarding their psychological functioning.
 ...
PMID:Asthma medication may influence the psychological functioning of children. 1528 58

We examined the efficacy and tolerability of augmentation with an extended release formulation of methylphenidate (OROS MPH, Concerta) in patients with major depression who were nonresponders or partial responders to antidepressants. Sixty subjects with treatment-resistant depression (TRD) participated in a 4-week, randomized, double-blind, placebo-controlled study of augmentation with methylphenidate (18-54 mg/d). The preexisting antidepressant dose was unchanged. The primary efficacy measure was change in the 21-item Hamilton Depression Rating Scale from randomization to end of treatment. Data were analyzed with intent-to-treat with last observation carried forward approach. There were no statistically significant differences between the methylphenidate (n = 30) and placebo (n = 30) groups in reduction in 21-item Hamilton Depression Rating Scale scores (drug, -6.9; placebo, -4.7) from baseline to end of treatment (F1,47 = 1.24, P = 0.22), although responders were numerically higher in the extended-release methylphenidate group (40.0%) than in the placebo group (23.3%). On the secondary efficacy measures of changes in Clinical Global Impression-Improvement and Severity scores and Beck Depression Inventory-Second Edition, the drug failed to separate from placebo, although the proportion of responders in the drug group were numerically higher than placebo. There were no significant differences in weight, heart rate, and blood pressure changes between the 2 groups. The common adverse events were loss of appetite, nausea, headache, and anxiety. The mean dose of drug was 34.2 mg/d. The study did not demonstrate a statistically significant benefit for augmentation with methylphenidate in TRD. Combination of methylphenidate with antidepressants was well tolerated. Adequately powered, randomized, controlled trials are necessary to fully evaluate the efficacy of extended-release methylphenidate in TRD.
 ...
PMID:A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. 1820 60

We experienced anesthesia care for two patients taking methylphenidate (Ritalin), which is a central nervous system stimulant of amphetamine analogues, usually administered for narcolepsy or refractory depression. The proper dose of methylphenidate is 20-60 mg per day. General anesthesia with epidural anesthesia was administered to both cases for total hip replacement. One patient could discontinue taking methylphenidate five days before the operation, but the other patient could not. Both cases needed more anesthetics than usual on induction, but very stable condition could be maintained during and after the operations. We consider that it is possible to perform general anesthesia safely for patients taking a usual dose of methylphenidate.
 ...
PMID:[General anesthesia for two patients taking methylphenidate (Ritalin)]. 1854 8


1 2 Next >>